Linsidomine | CAS#33876-97-0 | muscle relaxant

MedKoo Cat#: 584343 | Name: Linsidomine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Linsidomine is a smooth muscle relaxant that helps with unstable angina and opening human and quinea pig airways.

Chemical Structure

Linsidomine

CAS#33876-97-0

Theoretical Analysis

MedKoo Cat#: 584343

Name: Linsidomine

CAS#: 33876-97-0

Chemical Formula: C6H10N4O2

Exact Mass: 170.0804

Molecular Weight: 170.17

Elemental Analysis: C, 42.35; H, 5.92; N, 32.92; O, 18.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Linsidomine; CV 664

IUPAC/Chemical Name

3-Morpholinosydnone imine

InChi Key

FKDHHVKWGRFRTG-UHFFFAOYSA-N

InChi Code

InChI=1S/C6H10N4O2/c7-6-5-10(8-12-6)9-1-3-11-4-2-9/h5,7H,1-4H2

SMILES Code

[NH-]C1=C[N+](N2CCOCC2)=NO1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 170.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Sutherland FC, de Jager AD, Swart KJ, Hundt HK, Scanes T, Hundt AF. Determination of linsidomine in human plasma by tandem LC-MS with ESI. J Pharm Biomed Anal. 2000 Apr;22(3):461-7. PubMed PMID: 10766363. 2: Spreux-Varoquaux O, Doll J, Dutot C, Grandjean N, Cordonnier P, Pays M, Andrieu J, Advenier C. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis. Br J Clin Pharmacol. 1991 Sep;32(3):399-401. PubMed PMID: 1777378; PubMed Central PMCID: PMC1368538. 3: Stief CG, Holmquist F, Djamilian M, Krah H, Andersson KE, Jonas U. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. J Urol. 1992 Nov;148(5):1437-40. PubMed PMID: 1433545. 4: Prast H, Lamberti C, Fischer H, Tran MH, Philippu A. Nitric oxide influences the release of histamine and glutamate in the rat hypothalamus. Naunyn Schmiedebergs Arch Pharmacol. 1996 Dec;354(6):731-5. PubMed PMID: 8971733. 5: Delonca J, Giraud T, Beaufils P, Dupuis B, Haïat R, Théry C. Comparative efficacy of the intravenous administration of linsidomine, a direct nitric oxide donor, and isosorbide dinitrate in severe unstable angina. A French multicentre study. French Group of Investigators. Eur Heart J. 1997 Aug;18(8):1300-6. PubMed PMID: 9458423. 6: Laferrière A, Abaji R, Tsai CY, Ragavendran JV, Coderre TJ. Topical combinations to treat microvascular dysfunction of chronic postischemia pain. Anesth Analg. 2014 Apr;118(4):830-40. doi: 10.1213/ANE.0000000000000141. PubMed PMID: 24651238; PubMed Central PMCID: PMC4467972. 7: Lablanche JM, Grollier G, Lusson JR, Bassand JP, Drobinski G, Bertrand B, Battaglia S, Desveaux B, Juillière Y, Juliard JM, Metzger JP, Coste P, Quiret JC, Dubois-Randé JL, Crochet PD, Letac B, Boschat J, Virot P, Finet G, Le Breton H, Livarek B, Leclercq F, Béard T, Giraud T, Bertrand ME, et al. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem. Circulation. 1997 Jan 7;95(1):83-9. PubMed PMID: 8994421. 8: Chavanon O, Cracowski JL, Hacini R, Stanke F, Durand M, Noirclerc M, Blin D. Effect of topical vasodilators on gastroepiploic artery graft. Ann Thorac Surg. 1999 May;67(5):1295-8. PubMed PMID: 10355400. 9: Pastor CM, Losser MR, Payen D. Nitric oxide donor prevents hepatic and systemic perfusion decrease induced by endotoxin in anesthetized rabbits. Hepatology. 1995 Nov;22(5):1547-53. PubMed PMID: 7590674. 10: Sütsch G, Kim JH, Bracht C, Kiowski W. Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance. Clin Pharmacol Ther. 1997 Nov;62(5):538-45. PubMed PMID: 9390110. 11: Zhang Y, Palette-Pays C, Naline E, Varoquaux O, Advenier C. Effect of molsidomine and linsidomine on the human isolated bronchus and the guinea-pig isolated trachea. J Pharm Pharmacol. 1993 Apr;45(4):280-5. PubMed PMID: 8098368. 12: Weber AA, Strobach H, Schrör K. Direct inhibition of platelet function by organic nitrates via nitric oxide formation. Eur J Pharmacol. 1993 Sep 15;247(1):29-37. PubMed PMID: 8258358. 13: Spreux-Varoquaux O, Ulmer B, Cordonnier P, Forestier A, Pays M, Ducreuzet C, Advenier C. Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly. Fundam Clin Pharmacol. 1991;5(6):549-56. Erratum in: Fundam Clin Pharmacol 1991;5(7):566. PubMed PMID: 1955198. 14: Foucher-Lavergne A, Kolsky H, Spreux-Varoquaux O, Delonca J, Beaufils P. Hemodynamics, tolerability, and pharmacokinetics of linsidomine (SIN-1) infusion during the acute phase of uncomplicated myocardial infarction. J Cardiovasc Pharmacol. 1993 Dec;22(6):779-84. PubMed PMID: 7509893. 15: Wegner HE, Knispel HH, Klän R, Meier T, Miller K. Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction. Urol Int. 1994;53(4):214-6. PubMed PMID: 7855939. 16: Sennesael J, Verbeelen D, Degré S, Unger P, Stolear JC, Ostrowski J, von Hattingberg HM, Gaertner W. Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency. Int J Clin Pharmacol Ther Toxicol. 1993 Nov;31(11):533-41. PubMed PMID: 8294165. 17: Delonca J, Giraud T, Lennuyeux E, Charansonney O. [Linsidomine, direct donor of EDRF/NO: a new treatment for unstable angina]. Arch Mal Coeur Vaiss. 1996 Oct;89 Spec No 5:19-25. French. PubMed PMID: 8952816. 18: Gladis-Villanueva M, Schrör K. Synergistic inhibition of human polymorphonuclear function by prostaglandin E1 and linsidomine. J Pharm Pharmacol. 1996 Jul;48(7):706-11. PubMed PMID: 8866334. 19: Truss MC, Becker AJ, Djamilian MH, Stief CG, Jonas U. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology. 1994 Oct;44(4):553-6. PubMed PMID: 7941195. 20: Wegner HE, Knispel HH, Meier T, Klän R, Miller K. Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. Int Urol Nephrol. 1995;27(5):621-8. Review. PubMed PMID: 8775048.